Title
Retroperitoneal extramedullary hematopoietic pseudotumor in ataxia-telangiectasia.

Permalink
https://escholarship.org/uc/item/6ds6h4dm

Authors
Judge, Sean James
Plescia, Trevor A
Bateni, Cyrus P
et al.

Publication Date
2018

DOI
10.1177/2036361318789724

Peer reviewed
Retroperitoneal extramedullary hematopoietic pseudotumor in ataxia–telangiectasia

Sean James Judge¹, Trevor A Plescia¹, Cyrus P Bateni², Morgan A Darrow³, Christopher P Evans⁴ and Robert J Canter¹

Abstract
Ataxia–telangiectasia confers a significant increase in the development of several cancer types, most commonly leukemia and lymphoma. However, as the natural history for these patients is evolving and their lifespan is increasing, there is the potential for the development of additional uncommon tumors in an already rare patient population. We report the first case, to our knowledge, of an incidental retroperitoneal tumor in a 26-year-old woman undergoing evaluation for hepatic dysfunction. The mass was suspicious for retroperitoneal sarcoma, but proved to be an extramedullary hematopoietic pseudotumor after extensive pathologic evaluation. The changing landscape of neoplasms associated with ataxia–telangiectasia is discussed with emphasis on previously underreported benign and malignant tumors.

Keywords
Extramedullary hematopoietic pseudotumor, retroperitoneal sarcoma, ataxia–telangiectasia

Date received: 27 April 2018; accepted: 26 June 2018

Introduction
First described in 1941,¹ ataxia–telangiectasia (A-T) is a rare, autosomal recessive disorder with myriad characteristics, most notably cerebellar degeneration, telangiectasias, immunodeficiency, and cancer susceptibility.² The age of onset and rate of disease progression can vary widely, with typical onset of ataxia and telangiectasias at 1–4 years of age and 6 years of age, respectively.³ Average life expectancy for A-T patients is 26 years,⁴ and the most common causes of death are chronic lung disease and cancer.³

Following extensive molecular and genetic evaluation, the genetic defect responsible for A-T was localized to chromosome 11 in 1988,⁵ and ATM was subsequently identified as the culprit gene in 1995.⁶ Although the molecular mechanisms of A-T pathophysiology are not fully elucidated, ATM is known to play a critical role in regulation of the cell cycle, apoptosis, and response to DNA damage.³ Given the critical importance of the ATM gene in cellular function and DNA repair, it is clear that A-T patients are at high risk for various cancers, and the risk of malignancy is estimated at 61–184 times greater than the general population.⁸

Although several reports have demonstrated a clear link between A-T and hematological malignancies, an association with solid tumors is less established. Here, we describe the first reported case of a retroperitoneal tumor arising in a

¹Division of Surgical Oncology, UC Davis School of Medicine and UC Davis Cancer Center, Sacramento, CA, USA
²Department of Radiology, UC Davis School of Medicine, Sacramento, CA, USA
³Department of Pathology and Laboratory Medicine, UC Davis School of Medicine, Sacramento, CA, USA
⁴Department of Urology, UC Davis School of Medicine, Sacramento, CA, USA

Corresponding author:
Robert J Canter, Division of Surgical Oncology, UC Davis School of Medicine and UC Davis Cancer Center, Suite 3010, 4501 X Street, Sacramento, CA 95817, USA.
Email: rjcanter@ucdavis.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
patient with A-T. The mass was suspicious for a retroperitoneal sarcoma, but proved to be an extramedullary hematopoietic pseudotumor after thorough radiographic and pathologic evaluation. To our knowledge, this is the first reported case of extramedullary hematopoietic pseudotumor in an A-T patient and highlights the potential changing spectrum of neoplasms in A-T patients who are enjoying a longer lifespan because of improvements in multimodality care.

**Case report**

The patient is a 26-year-old woman with a childhood diagnosis of A-T, who suffers from the typical manifestations of the disease, including spastic paresis and frequent pulmonary infections as well as insulin-resistant diabetes mellitus, polycystic ovarian syndrome, osteopenia, and non-alcoholic steatohepatitis. She provided written informed consent for her case information to be published in the medical literature. It was during a hepatic ultrasound for evaluation of her liver disease that an incidental left retroperitoneal mass was discovered. Sonographic images of the abdomen demonstrated a 5.5 cm hypoechoic mass with internal vascularity in the left perirenal space which was potentially suspicious for malignancy (Figure 1(a)).

Further evaluation with a gadolinium-enhanced magnetic resonance imaging (MRI) revealed a $4.9 \times 2.9 \times 5.1$ cm enhancing retroperitoneal mass with T2 hyperintensity which exerted mass effect on the left kidney (Figure 1(b)). In addition, MRI demonstrated heterogeneous enhancement, restricted diffusion, and invasion into Gerota’s fascia, all of which were concerning for malignancy (Figure 1(c)).

An initial percutaneous biopsy was non-diagnostic, so the patient was referred for surgical evaluation. Computed tomography (CT) of the chest, abdomen, and pelvis, obtained for formal staging evaluation and surgical planning, revealed no evidence of metastases and confirmed the MRI findings of an extra-renal mass abutting the kidney with no clear evidence of invasion of the renal parenchyma.
(Figure 1(d)). A repeat image-guided needle biopsy was performed, but was again non-diagnostic despite several expert consultations. The biopsy material consisted of abundant myxoid stroma with a paucicellular proliferation of spindle to stellate cells, rare larger atypical cells with hyperchromatic nuclei, and background chronic inflammation. Immunohistochemical stains for MDM2, CDK4, keratin, desmin, SOX10, CD34, and MUC4 were negative, and FISH testing was negative for MDM2 gene amplification. The lack of staining for MDM2 and CDK4, as well as the negative FISH result, argued against a diagnosis of well-differentiated liposarcoma. Overall, the findings were non-specific, and the lesion was unable to be classified beyond a morphologically low-grade spindle cell neoplasm.

Given the patient’s significant comorbid conditions including restrictive lung disease, frailty, and dependent functional status (with corresponding high risk for postsurgical complications), the decision was made initially to observe the mass with active surveillance; 3 months after the second biopsy, repeat MRI showed interval tumor enlargement with irregular enhancement, thickening of Gerota’s fascia, and new mass effect on the abdominal wall (Figure 2).

Based on the follow-up MRI results, the decision was made to proceed with surgical excision using a left subcostal approach. Intraoperatively, the mass was found to be contiguous with and adherent to the left kidney. Based on these intra-operative findings, the mass was not amenable to separation from the kidney without excision of kidney parenchyma. Therefore, a left partial nephrectomy was performed, and no local/regional disease extension was noted. As shown in Figure 3(a)–(c), the mass was immediately adjacent to the renal capsule and had a similar histologic appearance to the prior core biopsy. Although the diagnosis of soft tissue myxoma was previously considered, immunohistochemical staining for CD61 was positive, highlighting rare large atypical cells which were consistent with megakaryocytes (Figure 3(d) and (e)). Given the constellation of clinical and histopathologic findings, a final diagnosis of extramedullary hematopoietic pseudotumor was ultimately rendered. Although the patient’s postoperative course was...
notable for persistent fevers and fatigue, no clear infectious etiology was identified. Despite a relatively prolonged postoperative course, the patient made a full recovery and was discharged home after approximately 2 weeks with return to baseline functional status. Following the diagnosis of extramedullary hematopoietic pseudotumor, the patient underwent a bone marrow biopsy to rule out bone marrow pathology. Despite the association of extramedullary hematopoietic pseudotumor with myelofibrosis, bone marrow studies showed normocellular marrow with adequate trilineal hematopoiesis, no significant reticulin fibrosis, and no increase in blasts.

**Discussion**

Although rare, the phenomenon of non-hepatosplenic extramedullary hematopoiesis (NHS-EMH) has been well described in the non-fetal population, but has never been previously reported in the A-T population. Much of the data pertaining to NHS-EMH come from a Mayo Clinic series of 27 patients between 1975 and 2002 published in 2003. In the study by Koch et al., NHS-EMH was most frequently associated with myelofibrosis with myeloid metaplasia and thalassemia, though several other associations were also documented. The underlying connection appears to be chronic anemia, with an average hemoglobin concentration measured in their series at 9.5 g/dL. The patient described in this report had a preoperative hemoglobin concentration consistently around 12 g/dL, suggesting that she should be at lower risk for EMH if the association of chronic anemia with NHS-EMH pseudotumor is mechanistically related. However, given the risk of hematologic malignancy with A-T, the development of NHS-EMH may represent an additional manifestation of myeloid pathology secondary to as yet unidentified causes.

As previously noted, the connection between cancer and A-T is well described. Specifically, observational data suggest that the cumulative incidence of cancer increases with age in A-T, measured at 10.4% at 10 years, 22.6% at 20 years, 29.9% at 30 years, and 38.2% at 40 years. The most common cancers are leukemia and lymphoma, whereas solid tumors are rarer and commonly associated with myelofibrosis with myeloid metaplasia and thalassemia, though several other associations were also documented. The underlying connection appears to be chronic anemia, with an average hemoglobin concentration measured in their series at 9.5 g/dL. The patient described in this report had a preoperative hemoglobin concentration consistently around 12 g/dL, suggesting that she should be at lower risk for EMH if the association of chronic anemia with NHS-EMH pseudotumor is mechanistically related. However, given the risk of hematologic malignancy with A-T, the development of NHS-EMH may represent an additional manifestation of myeloid pathology secondary to as yet unidentified causes.

Careful diagnostic workup is also critical for retroperitoneal masses, especially in A-T. Unlike the general population where radiation therapy (RT) has a role in treating retroperitoneal tumors, RT is contraindicated in A-T because of the risk of severe and even lethal toxicities. Therefore, accurate tissue diagnosis is required to guide the proper surgical resection and thereby oncologic outcome with strategies to limit post-surgical morbidity and mortality.

In this case, prior to the final diagnosis of an extramedullary hematopoietic pseudotumor, the leading diagnostic consideration based on the percutaneous biopsy results was soft tissue myxoma, another benign, mesenchymal neoplasm also characterized by bland spindle to stellate cells in myxoid stroma. These benign tumors are generally non-recurrent, although certain variants have demonstrated a small risk of local, non-destructive recurrence. Overall, there seems to be no correlation between A-T and retroperitoneal masses, although recent research has identified an interaction between the ATM protein and FUS/TLS (currently designated as DDIT3), a translocated gene identified in certain human liposarcomas. Despite this molecular connection, primary sarcomas arising in A-T patients are limited to two case reports—notably uterine leiomyosarcoma and Epstein–Barr virus (EBV)-associated laryngeal leiomyosarcoma. Though the propensity for cancer is a hallmark of A-T, the development of either primary sarcoma or extramedullary hematopoietic pseudotumor is equally rare, emphasizing the need for
careful multidisciplinary management of A-T patients who present with suspicious solid tumors.

**Conclusion**

Patients with A-T are at significantly increased risk of various cancer types, most notably leukemia and lymphoma. As more A-T patients live longer, other less common tumors are being identified. Given the association of A-T with several diseases that can lead to anemia, extramedullary hematopoietic pseudotumor should be on the differential diagnosis for atypical tumors arising in A-T, particularly in the retroperitoneum. Evaluation with comprehensive imaging modalities is essential, as is tissue diagnosis to aid definitive diagnosis and surgical planning. Given the complexities of caring for patients with A-T, evaluation, management, and treatment should be carried out in specialty centers where appropriate resources are available.

**Acknowledgements**

S.J.J. was involved in conception and design, literature review, and writing the manuscript. T.A.P., C.P.B., M.A.D., and C.P.E. participated in analysis and interpretation of data and critical revision of the article. R.J.C. was involved in conception and design, analysis and interpretation of data, writing the manuscript, and critical revision of the manuscript.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by funding from the Dr Mark Starr Family Fund.

**References**

1. Louis-Bar D. Sur un syndrome progressif comprenant des télangiectasies capillaires cutanées et conjonctivales a disposition naevoïde et des troubles cérébelleux. *Confin Neurol* 1941; 4(21): 32–42.
2. Rothblum-Oviatt C, Wright J, Lefton-Greif MA, et al. Ataxia telangiectasia: a review. *Orphanet J Rare Dis* 2016; 11(1): 159.
3. Gatti R and Perlman S. Ataxia telangiectasia. In: Adam MP, Ardinger HH, Pagon RA, et al. (eds) *GeneReviews*(r). Seattle, WA: University of Washington, 1993.
4. Crawford TO, Skolasky RL, Fernandez R, et al. Survival probability in ataxia telangiectasia. *Arch Dis Child* 2006; 91(7): 610–611.
5. Gatti RA, Berkel I, Boder E, et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. *Nature* 1988; 336(6199): 577–580.
6. Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. *Science* 1995; 268(5218): 1749–1753.
7. Shiloh Y and Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. *Nat Rev Mol Cell Biol* 2013; 14(4): 197–210.
8. Morrell D, Cromartie E and Swift M. Mortality and cancer incidence in 263 patients with ataxia telangiectasia. *J Natl Cancer Inst* 1986; 77(1): 89–92.
9. Koch CA, Li CY, Mesa RA, et al. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. *Mayo Clin Proc* 2003; 78(10): 1223–1233.
10. Suarez F, Mahlaoui N, Canioni D, et al. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. *J Clin Oncol* 2015; 33(2): 202–208.
11. McGrath-Morrow SA, Gower WA, Rothblum-Oviatt C, et al. Evaluation and management of pulmonary disease in ataxia-telangiectasia. *Pediatr Pulmonol* 2010; 45(9): 847–859.
12. Storm FK and Mahvi DM. Diagnosis and management of retroperitoneal soft-tissue sarcoma. *Ann Surg* 1991; 214(1): 2–10.
13. Tamminga RY, Dolsma WV, Leeuw JA, et al. Chemo- and radiosensitivity testing in a patient with ataxia telangiectasia and Hodgkin disease. *Pediatr Hematol Oncol* 2002; 19(3): 163–171.
14. Stout AP. Myxoma, the tumor of primitive mesenchyme. *Ann Surg* 1948; 127(4): 706–719.
15. Fletcher CDM, World Health Organization and International Agency for Research on Cancer. *The WHO classification of tumours of soft tissue and bone*. 4th ed. Lyon: IARC Press, 2013, p. 468.
16. Gardner M, Toth R, Vandermeure F, et al. Identification and characterization of FUS/TLS as a new target of ATM. *Biochem J* 2008; 415(2): 297–307.
17. Gatti RA, Nieberg R and Boder E. Uterine tumors in ataxia-telangiectasia. *Gynecol Oncol* 1989; 32(2): 257–260.
18. Reyes C, Abuzaitoun O, De Jong A, et al. Epstein-Barr virus-associated smooth muscle tumors in ataxia-telangiectasia: a case report and review. *Hum Pathol* 2002; 33(1): 133–136.